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Background: Cancer therapies have been shown to lead to cognitive impairments and is 
believed to involve early M1 proinflammatory microglial activation, a well-established indicator of 
neuroinflammation. IBA1 is a specific and established microglia marker, but the emerging marker 
for activated microglia, TSPO, can be used in live-imaging. We investigated the feasibility of using 
TSPO to determine activated microglia following chemo- and radiotherapy. 
Methods: Female and male C57Bl/6 mice were treated with 5-fluorouracil (5-FU) 400 
mg/kg vs saline (n=24), and culled between Day 1 and 32; or with 2 Gy and sham radiation and 
culled at Day 2 (n=7). Immunofluorescence staining was performed on brain sections for IBA1 and 
TSPO expression. The cerebellum, hippocampus dentate gyrus, CA1 and CA3, and prefrontal 
cortex were analysed by IBA1+ and TSPO+ cell counts and morphology index ratios in ImageJ. 
Results: TSPO+ counts increased significantly in the cerebellum and hippocampus 5FU 
Day 1 to 32 from 9.0±5.3 to 47.0±11.4, P=0.012; 14.3±4.5 to 76.7±25.5, P=0.0007 respectively. 
Counts also significantly increased in the cerebellum, hippocampus and prefrontal cortex, in 
controls Day 1 to 32 from 11.0±9.5 to 47.7±6.7, P=0.016; 14.3±3.5 to 88.3±22.5, P=0.0001; 
39.3±16.3 to 97.7±38.55, P=0.033, respectively. No significant differences were observed in 
IBA1+ cell counts beyond prefrontal cortex controls, between radiotherapy counts in treated and 
control animals, or in chemotherapy IBA1+ morphology index ratios. 
Conclusion: Our study found that TSPO+ but not IBA1+ cells increase with time in brain 
regions associated with cognitive impairment following chemotherapy, while both did not increase 
following radiotherapy. 
 
3. Introduction  
3.1 Background 
Cancer-related cognitive impairments (CRCI), such as problems with memory and focus, 
chronically affect up to 75% of non-central nervous system cancer survivors, lasting up to 20 years 
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after treatment for 1 in 4 survivors(1). The cancer therapies chemo- and radiotherapy have been 
shown to lead to cognitive impairments and structural brain changes in humans(1, 2). Based on 
various animal studies, the mechanisms responsible are believed to involve early proinflammatory 
microglial activation, a well-established indicator of neuroinflammation(3, 4). ‘Activated’ microglia 
may refer to either the M1 proinflammatory or M2 anti-inflammatory phenotypes; unless otherwise 
specified, for the purposes of this thesis ‘activated’ microglia will refer to the M1 phenotype(5). 
A moderate number of rodent studies have investigated microglial changes in the brain 
induced by chemo- and/or radiotherapy(3, 4, 6-12). Methotrexate was predominantly used as the 
chemotherapy, while radiotherapy was mostly head-targeted. These studies reported impacts on 
microglial number and/or morphology. The predominant analytical method was 
immunohistochemistry staining for ionised calcium binding adaptor molecule 1 (IBA1), a specific 
and established marker of resting and activated microglia(13). The less commonly used methods 
include the immunohistochemical staining of another activated microglia marker, CD68(4, 6, 9, 10, 12), 
microfluidic qPCR for activated microglial gene transcripts(6), and [11C]PK11195 radiotracer 
detection(11). Most studies have reported evidence for neuroinflammation, with a general increase in 
microglial numbers and morphological changes involving larger microglial bodies and thicker 
processes. Some studies reported decreases in microglial numbers in various areas shortly after 
chemotherapies cyclophosphamide, docetaxel, 5-fluorouracil (5-FU), or topotecan in the prefrontal 
cortex(8), or after whole-brain radiation in the dentate gyrus(9) compared to controls. The microglia 
impacts varied between brain regions, chemo- and radiotherapy doses, time of cull and age of 
animals.  
Limited understanding of the role of microglia in the pathogenesis of CRCI is due to a lack 
of consistency between studies in terms of type and dose of treatments, timing of investigation, 
tissue preparation and analyses, and brain regions assessed. Further, most studies only address 
chemo- or radiotherapy when both are used in cancer treatment, and there is a lack of non-brain 
directed radiation therapy (NBRT) models(3). Dey et al. 2020 found that the combination of 
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temozolomide chemotherapy and whole-brain radiation leads to an acute increase in activated 
microglia in the hippocampus(4). Feiock et al. 2016 reported that the neuroinflammatory response 
defined by microglial numbers and morphological changes induced by methotrexate versus NBRT, 
were statistically indistinguishable. There were increased numbers of IBA1-positive microglia in 
the rostral cortex, striatum, cerebellum, hippocampus and medulla, with morphological changes 
aligned with activation(3). 
Compared to methotrexate, limited studies have investigated the microglial changes induced 
by chemotherapeutic 5-FU, which has been shown to induce cognitive impairments in patients and 
animal models(14). It has been seen to reduce neurogenesis in the hippocampus in rodents(15), and it, 
as well as its derivatives have contributed to white matter changes reported in patients(16). 5FU is 
frequently used to treat breast, cervix and gastrointestinal cancers(14, 17) and is small enough to 
potentially cross the blood brain barrier, which may facilitate its damage to the brain(14). 
The limitation with existing methods in pre-clinical CRCI research, which rely on 
immunohistochemical detection of markers, is the requirement of necropsy tissue, which only 
allows one time point per animal and post-mortem assessment. There is an emerging marker for 
neuroinflammation, the upregulation of mitochondria outer membrane translocator protein (TSPO), 
which has been suggested to be involved in immune function and energy production(18). However, 
there has been a debate as to whether the upregulation of TSPO signifies pro- or anti-inflammatory 
phenotypes in glial cells(19). TSPO has been used in live-imaging and in vitro studies, as well as in 
clinical diagnosis(18-20), and current evidence is highly promising towards the upregulation of TSPO 
in proinflammatory glial cells(19). 
TSPO is largely undetectable in resting microglia by the current available techniques, 
however is greatly upregulated with neuroinflammation and microglial activation(20, 21). 
Neuroinflammation can be detected using PET imaging with TSPO radiotracers in vivo and in 
vitro(22); the in vivo live-imaging aspect is particularly beneficial as the progress of 
neuroinflammation (e.g. microglial activation) can be taken without sacrificing animals, which is 
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more clinically applicable than existing methods. However, the disadvantages of using TSPO to 
identify activated microglia is that it is expressed in other cells, including astrocytes, endothelial 
cells and pericytes, (19, 23, 24). Thus, while TSPO does have its advantages over IBA1 
immunohistochemical staining, it is not specific to microglia, which complicates the interpretation 
of expression and imaging results. Before TSPO can progress into clinical diagnostic protocols, a 
deeper understanding of the cells it detects, as well as its relationship to neuroinflammation 
following chemo- and radiotherapy is required. 
Ultimately, what remains unknown are the similarities and differences between the 
neuroinflammatory response induced between chemo- and NBRT radiotherapy, both of which are 
comparable as they are non-brain directed and systemic(25). And further, whether TSPO expression 
reflects the respective neuroinflammatory responses. 
3. 2 Hypothesis and aims 
I hypothesised that chemo- and radiotherapy respectively, will have comparable 
neuroinflammatory responses, which will be detectable via TSPO expression. To address my 
hypothesis, I aimed to determine IBA1 and TSPO expression in the brain following chemo- and 
radiotherapy exposure, respectively. 
 
4. Materials & Methods 
4.1 Ethics approval 
The chemotherapy study was approved by the South Australian Health and Medical 
Research Institute (SAHMRI) Animal Ethics Committee SAM435.19. The radiotherapy study was 
approved by the University of Sydney Animal Ethics Committee and the Australian Nuclear 
Science and Technology Organisation (ANSTO) Animal Care and Ethics Committee, Animal 
Research Authority P301. All procedures were aligned with the Australian Code of Practice for the 




4.2 Animal models 
All mice were housed with free access to food and water, under 12-hour light/dark cycle.  
In the chemotherapy study, 13-15-week old C57Bl/6 female mice obtained from SAHMRI 
Bioresources (South Australia) were treated with 5-FU 400 mg/kg(17) vs saline (control) via 
intraperitoneal injection (n=24) and followed up to 32 days. Mice were anaesthetised with 5% (v/v) 
of isoflurane and humanely culled by pentobarbitone overdose 125 mg/kg and transcardial saline 
perfusion. The treated mice were culled at Day 1, 2, 4, 8, 16, and 32, while the control mice were 
culled at Day 1 and 32 (n=3 per day per treatment); Day 1 represents 24 hours, and so on. A broad 
range of cull points were selected to address the inconsistency of investigation points in the 
literature. 
In the radiotherapy study, 6-week-old C57Bl/6 healthy male mice obtained from the Animal 
Resource Centre (Western Australia) were treated with 2 Gy(4) of whole-body gamma radiation at a 
dose of 0.08 Gy/minute (n=3) vs sham radiation (control) (n=4). Mice were humanely culled via 
isofluorane overdose and exsanguination on Day 2 after irradiation, at which microglial activation 
was previously demonstrated to peak in unpublished preliminary data from our collaborator’s 
laboratory. 
4.3 Tissue preparation 
In the chemotherapy study, brains were collected and fixed in 4% buffered 
paraformaldehyde and embedded in paraffin. 5 𝜇m sagittal sections at the level of the cerebellum, 
hippocampus, and prefrontal cortex, were obtained on a rotary microtome (Leica RM2235). 
Sections were floated in water at 38°C, placed on coated Flex IHC microscope slides (DAKO, 
Carpinteria, CA, USA). The tissue mounted slides were heated in an oven at 38°C overnight, then 
dewaxed in 3 rounds of histolene for 5 minutes each, and rehydrated through graded ethanol 100, 
90, and 70% for 1 minute each. 
In the radiotherapy study, brains were snap frozen in liquid nitrogen and stored at -80°C. 10 
𝜇m coronal sections at the level of the hippocampus were obtained on a cryostat (Leica CM3050) at 
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-18 to -20°C. Sections were placed on Poly-lysine slides (Thermo Scientific, Rockford, IL, USA) 
and stored at -80°C until use(24). The tissue mounted slides were blow dried for at least 30 minutes 
with cool air before staining. Tissue sections were fixed with 3.7% formaldehyde in PBS for 5 
minutes, then permeabilised with ice-cold acetone(24). 
4.4 Immunofluorescence 
Antigen retrieval was required for the chemotherapy study tissue, but not the radiotherapy, 
and was performed for 20 minutes at 97°C with a Tris-EDTA buffer (pH 9.0) in a DAKO PT Link 
water bath.  
Immunofluorescence staining for all tissue sections was performed on the DAKO 
Austostainer Plus, serial number AS1271F1104 (Via Real, California, USA). Tissue sections were 
twice rinsed with 1xPBS buffer. Non-specific antibody binding was blocked with 5% goat serum 
and 5% bovine serum albumin (BSA) in 1xPBS(24) for 60 minutes, followed by an air blow then 
buffer rinse. Primary antibodies rabbit TSPO rabbit monoclonal antibody (ab109497, Abcam)(24) 
and rabbit anti-Iba1 antibody (#019-19741, Wako)(26), were applied for 60 minutes at the 
concentration 1:200 (from stock 1 𝜇g/mL and 0.5 𝜇g/mL respectively) to separate sets of 
corresponding tissue, followed by two 1xPBS buffer rinses. Secondary reagent Alexa Fluor 488 
goat anti-rabbit IgG (ThermoFisher, Invitrogen, Catalog # A-11034) was applied at concentration 
1:1000 (from 2 mg/mL stock) for 60 minutes, followed by two 1xPBS buffer rinses. The nuclear 
stain 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich, Saint Louis, MO, 
USA, Catalog # D9542 and D8417) was applied at concentration 1:1000 (from 2 mg/mL stock) for 
15 minutes, followed by two 1xPBS buffer rinses. Sections were then mounted in Fluoroshield 
F6182 (Sigma-Aldrich, Saint Louis, MO, USA) and coverslipped with 22x22mm #1.5 coverslips 






4.5 Haematoxylin and eosin (H&E) 
H&E staining(10, 27) was performed on the tissue sections subsequent to tissue preparation on 
Superfrost microscope slides (Menzel-Gläser, Germany) for the chemotherapy study, and Poly-
lysine slides (Thermo Scientific, Rockford, IL, USA) for the radiotherapy study. 
4.6 Microscopy 
Scans for whole tissue sections were obtained at 40x objective via the Zeiss Axio Scan.Z1 slide 
scanner (Germany) for the immunofluorescent stained tissue, and the Nanozoomer (Hamamatsu 
Photonics, Japan) for the H&E stained tissue.  
4.7 Quantification 
Immunofluorescence images of 0.06mm2 for analysis were obtained via ZenBlue 3.1. 
Positively stained cells and fragments for IBA1 and TSPO were counted(7) by one observer and 
tallied via the Cell Counter plugin on ImageJ-win64, including cell bodies and fragments that were 
brighter than the background in the images. Morphological index of IBA1-postive cells were 
manually determined for microglia-like cells with clear soma and nuclei in the chemotherapy tissue. 
Any cells that were only partially captured due to the boundaries of the images were discounted. 
Morphological index was obtained via the average ratio of the soma area and the arborisation area 
(area created by joining the tips of the processes of a microglia cell) via ImageJ-win64(28). The 
radiotherapy tissue was excluded from morphological index analyses as fluorescence images 
obtained via the Zeiss Axio Scan.Z1 slide scanner did not show obvious microglia-like structures; 
however, presence of microglia-like cells was confirmed via the Olympus FLUOVIEW FV3000 
confocal microscope at 60x objective (data not shown). 
4.8 Statistical analyses 
Data was statistically analysed for significance via GraphPad Prism 8. Data passed the 
Shapiro-Wilk test for normality. One-Way ANOVA with post hoc testing via Tukey’s multiple 
comparisons was performed on the chemotherapy counts, Day 1 to 32 treated and controls for 
cerebellum, hippocampus CA1 and prefrontal cortex. Unpaired, parametric, two-tailed t-test was 
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performed on radiotherapy counts Day 2 treated and control, corresponding chemotherapy counts 
Day 1 control and Day 2 treated, and IBA1 chemotherapy morphology data for hippocampus 
regions dentate gyrus, CA1 and CA3. Significance was considered at level of *P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.00001, and data was represented as mean±SD 
 
6. Results 
6.1 IBA1+ and TSPO+ staining 
IBA1+ and TSPO+ immunofluorescence staining was identified via channel green staining 
for the chemo- cerebellum (Figure 1), hippocampus CA1 (Figure 2) and prefrontal cortex (figure 
not shown); and radiotherapy (Figure 3, 4, 5) tissues, which represented the fluorophore Alexa 




Figure 1. Left to right: H&E, IBA1 and TSPO immunofluorescence staining of chemotherapy 
cerebellum at 40x objective. Top to bottom, rows represent (A) Day1 Ctrl, (B) Day1 5FU, (C) 
Day2 5FU, (D) Day4 5FU, (E) Day8 5FU, (F) Day16 5FU, and (G) Day32 5FU. Day32 Ctrl not 
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included. Arrows examples of binding of IBA1 or TSPO antibodies. The blue in IBA1 and 
TSPO represents DAPI staining; the green represents the fluorophore Alexa Fluor 488, and 




Figure 2. Left to right: H&E, IBA1 and TSPO immunofluorescence staining of chemotherapy 
hippocampus CA1 at 40x objective. Top to bottom, rows represent (A) Day1 Ctrl, (B) Day1 
5FU, (C) Day2 5FU, (D) Day4 5FU, (E) Day8 5FU, (F) Day16 5FU, and (G) Day32 5FU. Day32 
Ctrl not included. Arrows examples of binding of IBA1 or TSPO antibodies. The blue in IBA1 
and TSPO represents DAPI staining; the green represents the fluorophore Alexa Fluor 488, and 
indicates the binding of IBA1 and TSPO antibodies respectively. 
 
Figure 3. Left to right: H&E, IBA1 and TSPO immunofluorescence staining of radiotherapy 
dentate gyrus at 40x objective. From top to bottom, rows represent (A) Day 2 0Gy, (B) Day 2 
2Gy. Arrows examples of binding of IBA1 or TSPO antibodies. The blue in IBA1 and TSPO 
represents DAPI staining; the green represents the fluorophore Alexa Fluor 488, and indicates the 





Figure 4. Left to right: H&E, IBA1 and TSPO immunofluorescence staining of radiotherapy 
hippocampus CA1 at 40x objective. Top to bottom, rows represent (A) Day 2 0Gy, (B) Day 2 
2Gy. Arrows examples of binding of IBA1 or TSPO antibodies. The blue in IBA1 and TSPO 
represents DAPI staining; the green represents the fluorophore Alexa Fluor 488, and indicates the 
binding of IBA1 and TSPO antibodies respectively. 
 
 
Figure 5. Left to right: H&E, IBA1 and TSPO immunofluorescence staining of the 
radiotherapy hippocampus CA3 at 40x objective. Top to bottom, rows represent (A) Day 2 
0Gy, (B) Day 2 2Gy. Arrows examples of binding of IBA1 or TSPO antibodies. The blue in 
IBA1 and TSPO represents DAPI staining; the green represents the fluorophore Alexa Fluor 488, 
and indicates the binding of IBA1 and TSPO antibodies respectively. 
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 6.1.1 Chemotherapy counts 
From the chemotherapy counts data (Figure 6), there was predominantly no significant 
changes to IBA1 expression, except between Day 1 vs 32 controls of the prefrontal cortex (Figure 
6; E). TSPO consistently showed significant increases in expression at later cull time points in both 





































Figure 6. Number of IBA1+ (A, C, E) and TSPO+ (B, D, F) cells following 5FU chemotherapy 
per ROI 0.06mm2. N=24. Statistical analyses via One-Way ANOVA and Tukey’s multiple 
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comparisons. Significance P≤0.05 (*) and data represented as mean ± SD. No significance seen in 
IBA1 staining for cerebellum (A) and hippocampus CA1 (C). Significance was seen for IBA1 
prefrontal cortex (E) Day1 vs 32 Ctrl (P=0.034); TSPO cerebellum (B) Day1 vs 32 Ctrl (P=0.019), 
Day1 vs 16 and 32 5FU (P=0.0025 and 0.012), and Day4 vs 16 5FU (P=0.011); TSPO hippocampus 
CA1 (D) Day1 vs 32 Ctrl (P=0.0001), Day1 vs 8, 16 and 32 (P=0.016, 0.0025 and 0.0007); and 
TSPO prefrontal cortex (F) Day1 vs 32 (P=0.034), Day1 vs 4 and 16 (P=0.037 and 0.0010), and 
Day2 vs 16 (P=0.018).  
  6.1.2 Radiotherapy counts 
There were no significant changes in the IBA1+ or TSPO+ counts from the radiotherapy 
tissue between 0 and 2 Gy radiation in the hippocampus regions dentate gyrus, CA1 and CA3 
(Figure 7). The radiotherapy counts were compared alongside the most feasible corresponding 
chemotherapy counterparts. The chemotherapy IBA1+ cell counts were observed to be higher than 
the corresponding radiotherapy counts, which may be due to the different planes of sectioning, and 
indicates that chemo- and radiotherapy groups are not comparable. Significant increases were seen 



























Figure 7. Number of IBA1+ (A, C, E) and TSPO+ (B, D, F) cells following either radio- or 
chemotherapy therapy (rad) per ROI 0.06mm2. N=3-4/group. Statistical analyses via unpaired, 
parametric, two-tailed t-test. Significance *P≤0.05, **P≤0.01 and data represented as mean ± SD. 
Significance observed in hippocampus CA1 TSPO (D) Day1 Ctrl vs Day2 5FU (P= 0.0079); and 
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hippocampus CA3 TSPO (F) Day1 Ctrl vs Day2 5FU (P= 0.014). No significance observed in 
dentate gyrus IBA1 (A) and TSPO (B); hippocampus CA1 IBA1 (C); and hippocampus CA3 (E). 
6.2 IBA1+ microglia morphology 
 6.2.1 Chemotherapy morphology 
Immunofluorescence staining for IBA1 had superior observable definition of 
ramified/resting microglia compared to TSPO (Figure 1). Morphology index ratios were quantified 
for chemotherapy IBA1 cerebellum, hippocampus dentate gyrus, CA1 and CA3, and prefrontal 

































Figure 8. Morphology index ratio of IBA1+ cells following 5FU treatment. Statistical analyses 
via unpaired, parametric, two-tailed t-test. Significance *P≤0.05, and data represented as mean ± 
SD. No significance was observed in cerebellum (A) Day1 Ctrl vs Day2 5FU; dentate gyrus (B) 
Day1 Ctrl vs Day2 5FU; hippocampus CA1 (C) Day1 Ctrl vs Day2 5FU; hippocampus CA3 (D) 





This is the first study to investigate TSPO expression in multiple brain regions of mice 
treated with 5FU and total body irradiation, respectively. 
 7.1 No detectable microglia activation in IBA1+ and TSPO+ chemotherapy counts 
For the chemotherapy study, lack of significant change in IBA1 expression, as well as the 
increase of TSPO expression from the Day 1 to 32 control, did go against current literature. Most 
studies have observed significant changes in IBA1 expression following chemotherapy. 
Interestingly, in human Alzheimer’s models, IBA1+ cell counts predominantly did not change 
between the affected and control samples with increased microglia activation(13). While the 
comparison is questionable due to the different models, it does highlight the lack of clarity 
surrounding detecting microglial activation. TSPO expression should not be largely detectable in 
microglia in otherwise healthy brains(20). Combining the IBA1 and TSPO results indicates that 
either the absence or presence of microglia activation are plausible. A potential explanation for a 
lack of microglia activation is that TSPO staining highlighted cells beyond activated microglia, such 
as astrocytes, endothelial cells or pericytes, which have been seen to express TSPO when co-
labelled with GFAP, CD31 and PDGFR𝛽 respectively(23, 24). Further, it has been suggested that 
increases in astrocyte TSPO expression precedes microglia TSPO expression in an Alzheimer’s 
disease model(23).  On the other hand, a potential explanation for a presence of microglia activation 
is that while the overall number of microglia was unchanged with treatment, there was an increased 
proportion of activated microglia. This would be consistent with the results reported by Seigers et 
al. 2010(7) where the proportion of activated microglia increased after treatment with methotrexate 
compared to controls, as well as that of the human Alzheimer’s models(13). If there was indeed 
microglia activation, it is more likely to be explained by the stress from handling of the animals 
than the chemotherapy due to the observed increase in the TSPO expression of the controls. This 
would be parallel to the study conducted by Iwata et al. 2016 which reported that hippocampal 
microglia in rats activated in response to stress two days after attaining learned helplessness, and 
21 
 
further, while total number of microglia did not significantly change, the number of activated 
microglia significantly increase(29).   
 7.2 No significant changes in morphology in IBA1+ cells following chemotherapy 
There were no significant changes in the morphology index ratio of IBA1+ cells in the 
chemotherapy groups between Day 1 control vs Day 2 5FU, cerebellum, hippocampus regions 
dentate gyrus, CA1 and CA3, and prefrontal cortex. Most studies that address microglia 
morphology are based on observation rather than quantification which complicates comparison 
between our results. Seigers et al. (2010) reported increased proportion of activated microglia, 
determined via observed morphology, significantly increased at 1 and 3 weeks after methotrexate 
treatment in the hippocampus compared to controls(7). Similarly, Feiock et al. (2016)(3) reported 
higher number of activated microglia with larger cell bodies and thicker processes 3 days after 
methotrexate in areas including the hippocampus and cerebellum compared to controls. These 
studies suggest that our method of morphological analysis was insufficient to detect change in 
response to chemotherapy. 
 7.3 No significant changes between radiotherapy sham and treated 
There were no significant changes between the radiotherapy sham (0 Gy control) and treated 
(2 Gy) animals. This is consistent with unpublished preliminary data from the laboratory of our 
collaborators. In comparison however, Feiock et al. (2016) treated mice with 16 Gy radiation to one 
hind limb and observed a significant increase to IBA1+ microglia in the hippocampus at Day 3(3). 
This suggests that our model was insufficient to produce significant changes in microglia. 
7.4 Radiotherapy cell counts were not comparable to chemotherapy counts 
The IBA1+ chemotherapy counts for the hippocampus regions dentate gyrus, CA1, and CA3 
were consistently higher than the corresponding radiotherapy counts. This indicates that the chemo- 
and radiotherapy counts were not comparable, which may be linked to a multitude of diverging 
variables, the most likely being the different sectioning planes, and perhaps the tissue preparation. 
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The results are contrary to Feiock et al 2016, which found no statistical significance between total 
number of microglia following methotrexate and NBRT after 3 days(3). 
7.5 Comparison of our IBA1+ cell counts to literature 
Seiger et al. 2016 investigated IBA1+ cell counts in response to 5FU. They reported, no 
significant differences in control vs  75mg/kg 5FU in the hippocampus after 3 and 15 weeks, and a 
significant decrease in from control to 5FU after 3 weeks in the prefrontal cortex, from 40 𝜇m 
unspecified-plane sections in male mice(8). After appropriate conversion to match the parameters of 
our study, our IBA1+ cell counts are proportionally higher in both the treated and controls for the 
hippocampus and prefrontal cortex. This indicates the potential of overcounting IBA1+ cells in our 
study. 
7.6 Limitations strengths 
The main limitation of our study was that IBA1 was not co-labelled with TSPO, CD68, or 
other antibodies associated with activated microglia. This made it impossible to identify which 
microglia were activated, and further to what extent did TSPO stain cells beyond microglia.  
While this study was limited to only two control points at Day 1 and 32, it was enough to 
enable the identification of the potential handling and stress confounder. This could potentially be 
resolved by reducing animal handling with automatic weighing mechanisms in housing cages(30).  
There were various inconsistencies between the chemo- and radiotherapy studies, which prevents 
meaningful comparisons between the two treatments. Most prominently, the tissue collection, 
processing and sectioning were contrary, paraffin-embedded sagittal for the chemotherapy study, 
and snap-frozen coronal for the radiotherapy. This is likely to have impacted the extent that IBA1 
and TSPO were detected in the tissues; chemotherapy tissue had consistently higher IBA1+ counts 
compared to radiotherapy in the controls. Brain sections were at different planes, sagittal for the 
chemotherapy study and coronal radiotherapy. This barred comparison of the cerebellum and 
prefrontal cortex between the treatments, and only enabled comparison for the hippocampus 
regions. Further, the animals were of opposite genders, female for the chemotherapy study, and 
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male for radiotherapy, which may have had impacts on microglia. An old study conducted by 
Mouton et al. (2002) reported that female mice 25-40% higher numbers of microglia and astrocytes 
compared to age-matched male mice(31). While this study may explain the higher number of IBA1+ 
cells in the corresponding chemotherapy animals to the radiotherapy counts, this requires 
confirmation with more recent studies and modern techniques. 
Using tumour-free animals is both a limitation and strength. It brings to question the clinical 
relevance of our study as cancer treatment is given to patients with tumours, however it is a strength 
as tumour presence could not act as a confounder, as it alone has been seen to contribute to 
cognitive impairments(32, 33) and increased microglia activation(34, 35). 
7.7 Future directions 
In future, using multiple measures to identify activated microglia will ensure more 
confidence in results. Co-labelling of IBA1 and TSPO to reveal where they overlap would facilitate 
distinguishing microglia from astrocytes and endothelial cells, and would increase the accuracy of 
the TSPO counts data. Alternatives would be to co-label with GFAP, CD31, PDGFR𝛽 to discount 
astrocytes, endothelial cells, and pericytes from the TSPO counts(24). Further, assessing the IL12/10 
ratio of samples may be valuable in confirming the presence of pro-inflammatory microglia, which 
secrete IL12, over anti-inflammatory microglia, which secrete IL10(5). 
Ultimately, live imaging with a TSPO radiotracer to track changes to TSPO expression would be 
valuable in determining the feasibility of use in a clinical setting. Limited studies, have availed the 
use of radiotracers to identify microglial activation induced by cancer therapies. Parente et al. 
2020(11) investigated the uptake of [11C]PK11195, a TSPO radiotracer, in the brain after varying 
concentrations of whole-brain radiation in rats. The study identified comparable uptake on Day 3 
between the treated and control groups, but found that on Day 31, the 25 Gy group had significantly 
higher uptake than the 10 Gy and control groups. However, [11C]PK11195 is believed to lack 
sensitivity in detecting microglial activation at low levels(36), which may explain the lack of 
significant difference on Day 3. Alternative TSPO radiotracers exists, including [18F]-DPA-713, 
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which has been shown to be specific to proinflammatory glial cells(19); as well as flutriciclamide 
([18F]GE180), which has good affinity for TSPO(37) and has been used in multiple sclerosis(38) and 
Alzheimer’s disease(39) animal models. However, both require further study to validate its feasibility 
to measure microglial activation induced by chemo- and radiotherapy.  
Pannell et al. 2020 have used TSPO radiotracer [18F]-DPA-713 in vivo along with in vitro 
methods to confirm upregulated TSPO expression in pro-inflammatory glia detection. Currently, no 
studies have investigated the use of the TSPO radiotracer [18F]GE180 in in vivo and in vitro 
imaging to compare and contrast microglial activation induced by chemo- and radiotherapy 
respectively. Further investigation of TSPO radiotracers may enable researchers to determine the 
timing and location of neuroinflammation, which can be used to improve target interventions. 
The outcome measures of our study were relatively subjective. To improve reliability of the cell 
count results, future studies could ensure there are at least two observers, which aligns with Seigers 
et al. 2010(7), where the values are not significantly different, and are averaged. Further, automating 
the morphology analysis may improve the reliability of the results(40). Further optimisation of 
immunofluorescence staining, especially for IBA1 staining on frozen tissue, may reduce 
background in immunofluorescence images and maintain observable microglia processes. 
7.8 Conclusion 
Overall, for the chemotherapy tissue, IBA1+ cell counts did not significantly change in the 
cerebellum, hippocampus CA1 and prefrontal cortex. The TSPO+ cell counts increased with later 
cull time points in both the treated and the control animals for the cerebellum, hippocampus CA1 
and prefrontal cortex, indicating that the results may be due to stress-related to handling. There 
were no significant changes between radiotherapy treated and controls in the hippocampus regions 
dentate gyrus, CA1 and CA3. Additionally, there were no significant changes in the morphology 
index ratio between Day 1 control and Day 2 5FU in the cerebellum, hippocampus regions dentate 
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